Literature DB >> 1972484

Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus.

M A Khamashta1, R Cervera, R A Asherson, J Font, A Gil, D J Coltart, J J Vázquez, C Paré, M Ingelmo, J Oliver.   

Abstract

A prospective echocardiographic study was carried out on 132 consecutive patients with systemic lupus erythematosus (SLE) derived from three European university medical centres. The prevalence of valvular lesions in patients with SLE was 22.7% compared with 2.9% in a control group of 68 healthy volunteers. 50 SLE patients had antibodies against phospholipids. The prevalence of valve vegetations (8/50 [16%]) and of mitral regurgitation (19/50 [38%]) was significantly higher among the SLE patients with antiphospholipids than among those without (1 and 10/82 [1.2% and 12%], respectively). During follow-up of the patients with valvular lesions, haemodynamically significant clinical valve disease developed in 6 but surgery was required in only 1; 9 had cerebrovascular occlusions; and 7 died, although no death was due directly to the cardiac involvement. Thus, valvular heart disease, particularly affecting the mitral valve, is common in patients with SLE, and the presence of antibodies against phospholipids is associated with a higher prevalence of valvular abnormalities in these patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1972484     DOI: 10.1016/0140-6736(90)91373-i

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  46 in total

Review 1.  Acute myocardial infarction in young adults: causes and management.

Authors:  S Osula; G M Bell; R S Hornung
Journal:  Postgrad Med J       Date:  2002-01       Impact factor: 2.401

Review 2.  Cardiac valvulopathy in the antiphospholipid syndrome.

Authors:  Shaul Lev; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2002-12       Impact factor: 8.667

3.  Antiphospholipid Antibody Syndrome.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-09       Impact factor: 3.598

Review 4.  Antiphospholipid antibodies and cardiovascular disease.

Authors:  H L Beynon; M J Walport
Journal:  Br Heart J       Date:  1992-04

5.  Antiphospholipid antibodies: which and when?

Authors:  R Cervera; J Font; M A Khamashta; G R Hughes
Journal:  Postgrad Med J       Date:  1990-11       Impact factor: 2.401

6.  Addison's disease, hypertension, renal and hepatic microthrombosis in 'primary' antiphospholipid syndrome.

Authors:  S Inam; K Sidki; A R al-Marshedy; R Judzewitsch
Journal:  Postgrad Med J       Date:  1991-04       Impact factor: 2.401

Review 7.  [Cardiovascular manifestations in inflammatory rheumatic diseases].

Authors:  U Lange; J Strunk
Journal:  Z Rheumatol       Date:  2005-02       Impact factor: 1.372

Review 8.  The antiphospholipid syndrome: a syndrome in evolution.

Authors:  R A Asherson; R Cervera
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

Review 9.  Antiphospholipid antibodies in young adults with stroke.

Authors:  Robin L Brey
Journal:  J Thromb Thrombolysis       Date:  2005-10       Impact factor: 2.300

10.  [Cardiovascular monitoring of patients with systemic lupus erythematosus].

Authors:  H Schotte; H Becker; W Domschke; M Gaubitz
Journal:  Z Rheumatol       Date:  2005-11       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.